Assessment of Lipid Levels in Newly Diagnosed Diabetic Obese Patients Treated with GLP-1 Inhibitors Using MRI-PDFF

Motivation: GLP-1 receptor agonists have shown favorable effects in improving obesity and ectopic fat deposition in type 2 diabetes patients. MRI-PDFF can serve as a tool for continuous, dynamic assessment of lipid content changes in patients. Goal(s): Dynamic monitoring of fat content and lipid deposition changes in type 2 diabetes obese patients receiving glucagon-like peptide-1 receptor agonist treatment using MRI-PDFF. Approach: 21 male diabetic patients received 3-month treatment: semaglutide (n=12) or loxenatide (n=9). Clinical data collected, pre/post 3.0T MRI scans (T1WI, T2WI, MRI-PDFF) measured fat. Results: The semaglutide group showed significant fat reduction in multiple organs, while the loxenatide group reduced pancreatic fat fraction. Impact: Semaglutide effectively controls blood glucose and body weight in type 2 diabetes obese patients. It also significantly reduces SAT and VAT while alleviating ectopic fat deposition. MRI-PDFF represents a non-invasive tool for continuous assessment of lipid content changes following treatment.